图书馆订阅: Guest
Begell Digital Portal Begell 数字图书馆 电子图书 期刊 参考文献及会议录 研究收集
肿瘤形成评论综述™
SJR: 0.631 SNIP: 0.503 CiteScore™: 2

ISSN 打印: 0893-9675
ISSN 在线: 2162-6448

肿瘤形成评论综述™

DOI: 10.1615/CritRevOncog.2018021355
pages 255-262

Serum Levels of Soluble FLT3 Ligand in Patients with Active Multiple Myeloma Constitute Marker of Bone Marrow Plasma Cell Proliferative Activity

Maria Kokonozaki
Hematology Laboratory, University Hospital of Heraklion, Heraklion, Greece
Peggy Kanellou
Hematology Department, University Hospital of Heraklion, Heraklion, Greece
Constantine A. Pappa
Internal Medicine Department, Venizeleio General Hospital of Heraklion, Greece
Rodanthi Vyzoukaki
Hematology Laboratory, University Hospital of Heraklion, Heraklion, Greece
Styliani Sarantoulaki
Department of Pneumonology, University Hospital of Heraklion, Heraklion, Greece
Emilia Stavroulaki
Hematology Department, Venizeleio General Hospital of Heraklion, Greece
Stavroula Kyriakaki
Hematology Department, University Hospital of Heraklion, Heraklion, Greece
Athanasios Alegakis
School of Medicine, University of Crete, Heraklion, Greece
Anna Boula
Hematology Department, Venizeleio General Hospital of Heraklion, Greece
Michael G. Alexandrakis
School of Medicine, University of Crete, Heraklion, Greece

ABSTRACT

The FLT3-ligand is a molecule implicated in hematopoiesis. The aim of the present study was to detect any possible connections between serum levels of FLT3-L and multiple myeloma (MM) proliferation markers, such as serum levels of interleukin-6 (IL-6), B-cell activating factor (BAFF), beta-2 microglobulin (B2M), CRP and LDH, as well the percentage of bone marrow infiltration and the plasma cells' proliferation marker Ki-67 PI. We measured the above parameters in 58 patients with active MM. All circulating markers were significantly higher in MM patients compared to controls (p < 0.001 for all cases), and all values were increasing in parallel with disease stage (p < 0.001 for all cases). Positive correlations between FLT3-L were noted with serum levels of BAFF (p < 0.003), IL-6 (p < 0.002), CRP (p < 0.0001), LDH (p < 0.001), and BM Ki-67 PI (p = 0.012), whereas only trends of correlation were noted with the B2M value and the percentage of infiltration. It seems that the increased serum levels of circulating FLT3-L, in parallel with MM activity, reflect their increased presence in the bone marrow microenvironment, probably as an effect of increased angiogenesis and myelosuppression. Consequently, they are potential markers of disease activity.